

CORRECTION

Open Access



Correction to: Alantolactone selectively ablates acute myeloid leukemia stem and progenitor cells

Yahui Ding¹, Huier Gao², Yu Zhang², Ye Li¹, Neil Vasdev^{3,4}, Yingdai Gao², Yue Chen¹ and Quan Zhang^{1*}

Correction to:

Journal of Hematology & Oncology (2016) 9:93
<https://doi.org/10.1186/s13045-016-0327-5>

The original article [1] contains an error in Fig. 4b, the panel of colonies of 5 μ M Ara-C treatment was unintentionally duplicated onto the colonies of 2.5 μ M alantolactone treatment. The error was mistakenly introduced in

image integration when organizing the figures. However, the error has no bearing on the work's scientific conclusions as the statistical results are based on the correct pictures. The authors apologize to the editor and readership of Journal of Hematology & Oncology for any inconvenience caused.

The original article can be found online at <https://doi.org/10.1186/s13045-016-0327-5>.


*Correspondence: zhangquan612@163.com

¹ State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy and Tianjin Key Laboratory of Molecular Drug Research, Nankai University, Haihe Education Park, 38 Tongyan Road, Tianjin 300353, People's Republic of China

Full list of author information is available at the end of the article



© The Author(s) 2021. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.



Author details

¹ State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy and Tianjin Key Laboratory of Molecular Drug Research, Nankai University, Haihe Education Park, 38 Tongyan Road, Tianjin 300353, People's Republic of China. ² State Key Laboratory of Experimental Hematology, Institute of Hematology and Hospital of Blood Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin 300020, People's Republic of China. ³ Division of Nuclear Medicine and Molecular Imaging, Gordon Center for Medical Imaging, Massachusetts General Hospital, 55 Fruit St., Boston, MA 02114, USA. ⁴ Department of Radiology, Harvard Medical School, 55 Fruit St., Boston, MA 02114, USA.

Published online: 15 April 2021

Reference

1. Ding Y, Gao H, Zhang Y, Li Y, Vasdev N, Gao Y, Chen Y, Zhang Q. Alantolactone selectively ablates acute myeloid leukemia stem and progenitor cells. *J Hematol Oncol*. 2016;9:93.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

